

Participant flow

| | |
|------------------------------|----|
| Consented: | 52 |
| Screen Failure/Disqualified: | 0 |
| Randomized to treatment: | 52 |
| Withdrawal/Dropped: | 0 |
| Completed: | 52 |

Baseline characteristics

| Demographic | Statistic or Category | Value |
|-------------|---------------------------|--------------|
| Age (Years) | N | 52 |
| | Mean (SD) | 46.1 (16.43) |
| | Min. - Max. | 18 - 74 |
| Ethnicity | Hispanic or Latino | 1 (2%) |
| | Not Hispanic or Latino | 51 (98%) |
| Race | Asian | 7 (13%) |
| | Black or African American | 8 (15%) |
| | Multiracial | 1 (2%) |
| | White/Caucasian | 36 (69%) |
| Sex | Female | 30 (58%) |
| | Male | 22 (42%) |

Outcome measures

| Baseline Results Analysis of Covariance for Crossover Designs Turesky Modified Quigley-Hein Plaque Index | | |
|--|--------------------|----------------------|
| Treatment | Adjusted Mean (SE) | p-value ^a |
| Whole Mouth Average TQHPI (Error Variance=0.023) | | |
| Oral-B Clic with Ultimate Clean replaceable brush head | 2.57 (0.04) | 1 |
| Oral-B Cross Action 720 (Positive Control) | 2.57 (0.04) | |
| ^a Two-sided p-value for the baseline treatment comparison. | | |

| Change from Baseline Efficacy Results Analysis of Covariance for Crossover Designs ^{a b} Turesky Modified Quigley-Hein Plaque Index | | | | | |
|--|--------------------|------------------------------|----------------------|--|--|
| | | | | Treatment Difference (SE) | 2-sided P-value 95% CI |
| Treatment | Adjusted Mean (SE) | Percent Change from Baseline | P-value ^c | Oral-B Cross Action 720 (Positive Control) | Oral-B Cross Action 720 (Positive Control) |
| Whole Mouth Average TQHPI (overall baseline mean=2.57, error variance=0.025) | | | | | |
| Oral-B Clic with replaceable Ultimate Clean brush head | 1.52 (0.025) | 59% | <0.001 | 0.15 (0.022) | <0.001 (0.11, 0.20) |
| Oral-B Cross Action 720 (Positive Control) | 1.36 (0.025) | 53% | <0.001 | | |
| ^a Carryover effect in Baseline (pre-brushing) plaque was not significant and the effect was not included into the plaque reduction model. ^b Final model: Score = baseline + period + trt, Random subject. ^c Tests mean change from baseline versus 0. | | | | | |

Adverse events

There were no Adverse Events reported in this study.